Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG670

—

fba4f4bd-834d-5f6f-ac79-0a73092a1636

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • NOTCH_SIGNALING+0.416
  • MITOTIC_SPINDLE+0.352
  • HEDGEHOG_SIGNALING+0.331
  • WNT_BETA_CATENIN_SIGNALING+0.299
  • G2M_CHECKPOINT+0.276
  • TNFA_SIGNALING_VIA_NFKB+0.270
  • CHOLESTEROL_HOMEOSTASIS+0.191
  • HYPOXIA+0.170
  • HEME_METABOLISM+0.166
  • ESTROGEN_RESPONSE_LATE+0.163

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.362
  • OXIDATIVE_PHOSPHORYLATION-0.256
  • MYC_TARGETS_V2-0.236
  • INTERFERON_GAMMA_RESPONSE-0.219
  • MYC_TARGETS_V1-0.209
  • FATTY_ACID_METABOLISM-0.201
  • DNA_REPAIR-0.192
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.147
  • PANCREAS_BETA_CELLS-0.108
  • ALLOGRAFT_REJECTION-0.101

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG984
mng-umap@100
——0.779
2MNG435
mng-umap@100
——0.728
3TCGA-56-8308-01A-11R-2296-07
lung-landscapes@6
—cohortSQ20.725
4SRR17866851
colon-landscapes@1
——0.719
5TCGA-85-A50M-01A-21R-A262-07
lung-landscapes@6
—cohortSQ10.712
6MNG683
mng-umap@100
——0.699
7MNG471
mng-umap@100
——0.677
8MDT-AP-0223
medullo-epn-umap@date-based
MedMedulloblastoma0.659
9TCGA-BL-A13J-01A-11R-A10U-07
bladder-landscape@3
——0.637
10SJEPD030782_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.637

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
NOTCH_SIGNALING0.416Inavolisib— uncovered
MITOTIC_SPINDLE0.352Inavolisib— uncovered
HEDGEHOG_SIGNALING0.331Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.299Inavolisib— uncovered
G2M_CHECKPOINT0.276Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.270Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.191Remibrutinib— uncovered
HYPOXIA0.170Idelalisib— uncovered
HEME_METABOLISM0.166Temsirolimus— uncovered
ESTROGEN_RESPONSE_LATE0.163Idelalisib— uncovered
APICAL_SURFACE0.153Temsirolimus— uncovered
TGF_BETA_SIGNALING0.127Inavolisib— uncovered
APICAL_JUNCTION0.121Inavolisib— uncovered
GLYCOLYSIS0.111Inavolisib— uncovered
SPERMATOGENESIS0.099Inavolisib— uncovered
UV_RESPONSE_DN0.099Inavolisib— uncovered
APOPTOSIS0.097Idelalisib— uncovered
BILE_ACID_METABOLISM0.082Inavolisib— uncovered
E2F_TARGETS0.053Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.048Inavolisib— uncovered